Hosted by Seaver College, Natural Science Division Malibu Campus, Smothers Theatre | February 25, 2026 | 8:00 AM - 3:00 PM
Seaver College at Pepperdine University is proud to host the inaugural Pepperdine
Oncology Symposium on February 25, 2026. The event brings together students, faculty,
alumni, and community members to celebrate innovations in cancer therapy, tracing
the full continuum from basic and translational research to clinical application.
The symposium emphasizes Pepperdine’s commitment to serving those in need through
meaningful scientific advancement and compassionate healthcare leadership.
Julie R. Gralow, is executive vice president and chief medical officer for the American
Society of Clinical Oncology (ASCO). She is a breast medical oncologist and Professor
Emeritus of Medical Oncology and Global Health at the University of Washington School
of Medicine. Gralow is the former executive officer for Breast and Lung Cancer and
vice chair of the Breast Cancer Committee for the SWOG Cancer Clinical Trials Network.
In her role as CMO, Gralow serves as a public spokesperson for ASCO. She directly
oversees ASCO’s Center for Research and Analytics, Policy and Advocacy Department,
Care Delivery Department, and Center for Global Impact. She is committed to improving
quality of life for cancer patients, and is cofounder of Team Survivor Northwest,
a nonprofit organization aimed at helping female cancer survivors improve their health
through fitness and exercise, and the Women’s Empowerment Cancer Advocacy Network
to support cancer advocacy and education in low- and middle-income countries. She
received the 2018 ASCO Humanitarian Award for her work in empowering women cancer
patients globally. Gralow earned an MD from the University of Southern California,
served her residency at Harvard Medical School/Brigham and Women’s Hospital, and earned
a fellowship in medical oncology at University of Washington School of Medicine/Fred
Hutchinson Cancer Center.
Patient Story
Teri Pollastro
Teri Pollastro was diagnosed with HER2+ metastatic breast cancer in 2003, at a time
when her children were just 3 and 7 years old. Her treatment has included chemotherapy,
Herceptin, stereotactic body radiation therapy (SBRT), and participation in a Phase
1 vaccine clinical trial. She continues to receive Herceptin today.
Pollastro is deeply involved in cancer advocacy at both the local and national levels.
She serves as a patient advocate on numerous Department of Defense grants and is one
of four advocates in the Translational Breast Cancer Research Consortium. She works
closely with the University of Washington Cancer Vaccine Institute and serves on its
Patient Advisory Board. Additionally, she is a member of the advisory group for the
Fred Hutch MET-X program, which supports patients living with all types of metastatic
cancer, and she meets with newly diagnosed metastatic breast cancer patients as needed.
Pollastro has served as co-chair of the Northwest Metastatic Breast Cancer Conference
in Seattle, Washington; as co-chair of the MBCA Research Task Force; as a member at
large of the MBCA Executive Group; as an advocate on the ASCO Research Task Force
Committee; and as a patient advocate representing the University of Washington for
theTranslational Breast Cancer Research Consortium.
Agenda
The symposium opens with an oncologist–patient pairing, grounding the day in its true
purpose: the lives touched and transformed by innovation in cancer care.
The program continues with our Leaders in Drug Development Panel, featuring experts
shaping the next generation of cancer therapies.
The event concludes with undergraduate research in basic and translational oncology,
highlighting Pepperdine’s commitment to fostering future leaders in healthcare, science,
and service.
8:00 AM (PST) Check-in
8:30 AM (PST) Program Begins and Welcome
9:00 AM – 10:00 AM (PST) Keynote and Patient Story
10:00 AM – 11:00 AM (PST) Leaders in Drug Development Panel
Sara Hurvitz, professor of medicine, is a medical oncologist and clinical research
leader at the University of Washington School of Medicine where she serves as division
head of Hematology/Oncology. She is also the senior vice president of the Clinical
Research Division and is honored with the Smith Family Endowed Chair in Women's Health
at the Fred Hutchinson Cancer Center. As an international expert in breast oncology
and a leader in clinical and laboratory-based oncology research with extensive experience
leading clinical trials in all phases, Hurvitz led the breast cancer clinical trials
program at the University of California, Los Angeles, for 17 years and was medical
director of the Jonsson Comprehensive Cancer Center until 2023 when she accepted her
position at UW/FHCC. Hurvitz has won numerous awards, among them the Marni Levine
Memorial Breast Cancer Research Award 2008 through 2015 and the European Society of
Medical Oncology Breast Cancer Award in 2023. She has an active clinical practice
specializing in the treatment of women with breast cancer and continues to be involved
in designing, implementing, and leading multiple national and international clinical
trials testing new targeted therapies. Hurvitz earned her MD from the University of
Southern California. At UCLA, she served an internship/residency, was chief resident
of internal medicine, and completed a hematology-oncology fellowship in 2006. Hurvitz
is board certified in internal medicine, hematology, and medical oncology.
Andrew McKenzie joined the Sarah Cannon Research Institute (SCRI) in 2015 and serves
as the vice president of its Personalized Medicine program. He also serves as the
scientific director for Genospace, SCRI's fully integrated personalized medicine engine.
McKenzie has more than 10 years of basic science and translational research experience
in oncology. In his current role, he is responsible for providing scientific and operational
oversight for implementing SCRI’s personalized medicine strategy, which provides scientific,
consultative, and programmatic services to clinical research investigators, study
sponsors, research personnel, and other healthcare providers to advance SCRI’s molecular
profiling efforts. As scientific director at Genospace, McKenzie is responsible for
providing scientific and strategic guidance to data science and product development
activities.
Prior to joining SCRI, McKenzie was a research fellow in the Cancer Biology Department
at Vanderbilt University's Vanderbilt-Ingram Cancer Center, where he investigated
extracellular vesicle trafficking and translational cell biology research. He earned
a PhD in pharmacology from the University of Vermont, where he investigated extracellular
matrix remodeling and cell motility.
Lindsey Murphy practices as a pediatric oncologist at City of Hope Children’s Cancer
Center, where she joined the faculty as an assistant professor in 2023. She is also
the medical director for the School of Physician Assistant Studies at Pepperdine University
College of Health Science, which will enroll the first class of students in 2027.
Murphy is a physician-scientist with multiple lines of investigation aiming to advance
leukemia treatment by identifying potential new biomarkers for targeted therapies
(including CAR T cell therapies) and translating those into clinical trials as novel
therapeutic approaches for relapsed and refractory pediatric leukemia. Other investigations
focus on improving the process of treatment itself in stem cell transplantation,chemotherapy,
and oncology inpatient care.Murphy specializes in pediatric hematology/oncology because
it allows her to build long-term relationships with her young patients and their caregivers.
Inspired by their resilience and strength, she stays at the leading edge of her field
so that she can introduce families to the latest therapies, specifically those that
minimize harmful and long-lasting side effects.
She received her bachelor’s degree in biology and applied mathematics from Pepperdine
University and thereafer earned an MD from the University of Nevada School of Medicine.
She completed a pediatric residency at the University of Washington/Seattle Children’s
Hospital follow by a fellowship in pediatric hematology, oncology, and bone marrow
transplant at the University of Colorado/Children’s Hospital Colorado. She holds dual
board certification in pediatrics and pediatric hematology/oncology. She also completed
a master’s degree in clinical science at the University of Colorado, which allowed
her to gain additional experience with clinical trial design and clinical research
conduct. She has gained extensive experience with early phase clinical trials in children
with relapsed malignancies and serves as the primary investigator for several early
phase trials investigating the role for novel diagnostic and therapeutic techniques
in the treatment of pediatric leukemia.
Shahryar (Shay) Ashouri is a clinical professor of medicine at the David Geffen School
of Medicine at the University of California, Los Angeles. He currently sees patients at the UCLA hematology/oncology practice in Westlake Village, California. Ashouri demonstrates his primary objective—service
to his patients and community—by offering his patients state-of-the-art, personalized cancer
management, including involvement in appropriate clinical trials, while providing a calm and familiar
atmosphere close to their home. He creates a comprehensive treatment strategy for
each of his patients that not only assists them in fighting their disease, but also
maintains their high quality of life. He sees patients with breast cancer, urologic
cancers, gastrointestinal cancers, gynecologic cancers, and lung cancer, as well as
lymphomas.
Ashouri is a board-certified, fellowship-trained hematologist and medical oncologist.
He earned his medical degree at the University of Southern California’s Keck School of Medicine
and completed an internship and residency in internal medicine at the University of Southern California
and Los Angeles County Medical Center. Ashouri received his fellowship training in hematology and
medical oncology at USC’s Norris Comprehensive Cancer Center.
Dee Anna Smith is the chief executive officer (CEO) of Sarah Cannon Research Institute
(SCRI), one of the world’s leading oncology research organizations conducting community-based
clinical trials.
Under her leadership, SCRI formed a joint venture with US Oncology Research in 2022,
bringing together physicians who are actively helping patients access clinical trials
at more than 250 locations in 24 states across the US. Smith is responsible for leading
the organization’s overall mission and vision to make a global impact on the next
generation of cancer care.
Smith has devoted the last two decades of her career to transforming oncology research
and how it influences care from diagnosis through survivorship. Prior to creating
the SCRI joint venture, she served as CEO for Sarah Cannon, the Cancer Institute
of HCA Healthcare. During her tenure, the company has experienced exponential growth
in serving more patients across its care network, and conducted pivotal clinical research
that has led to the majority of newly approved cancer therapies now available to patients.
Smith’s commitment to serving communities affected by cancer was born from her entrepreneurial
mindset. After graduating from Pepperdine with a degree in accounting, she began her
career as an auditor and Certified Public Accountant (CPA) with one of the world’s
largest accounting firms, KPMG. Through her six years of audit work, she was inspired
by the power of technology innovation and its potential to improve clinical research.
Over the next 12 years, Smith founded two companies focused on clinical trial services;
the first startup was acquired by Oracle, and the second was acquired by HCA Healthcare
to become a part of Sarah Cannon’s research platform.
Guided by her faith, Smith has always had a passion for helping those in need. She
was selected by the Association to Advance Collegiate Schools of Business International
(AACSB) as a member of its 2021 Class of Influential Leaders. In November 2020 she
was named one of Pepperdine University’s Outstanding Alumni in Healthcare and was
the recipient of the University’s Distinguished Alumnus Award in 2019. In October
2017 Smith was recognized by Nashville-based Operation Andrew as a Rodgers Award recipient
for making an impact on lives and communities in Middle Tennessee and beyond. In 2013,
she was named a Health Care Hero by the Nashville Business Journal and also received
the Heroes of Business Award from Lipscomb University.
Smith is a member of the American Institute of Certified Public Accountants and American
Society of Clinical Oncology. She serves as the chair of Pepperdine’s Board of Regents
and is an active member of Ethos Church in Nashville, Tennessee.
Madison Johnson is a senior biology major with a minor in German on the pre-medicine
track in the Regents Scholars Program at Pepperdine University. Her oncology research
experience bridges academic and clinical settings, informed by her internships with
the Cancer Epigenomics Division at the German Cancer Research Center in Heidelberg
and the Personalized Medicine program at Sarah Cannon Research Institute in Nashville.
Johnson’s work includes cancer immunotherapy development, epigenetic approaches in
oncology, and personalized medicine within clinical trials. She is the founder of
Pepperdine’s inaugural Oncology Symposium and serves as president of the University’s
Pre-Medicine Club. On campus Johnson is an undergraduate researcher in the Gomez Laboratory,
a biology teaching assistant, and a tour guide for the Office of Admission.